

Emergency contact information:

Emergency Prescriber Contact:

Telephone number during office hours:

Telephone number after office hours:

For complete information on the side effects of pomalidomide, patients should read the Package Leaflet and HCPs should read the Summary of Product Characteristics.

Version: 1.0
Date: December 2022

This document has been reviewed and approved
by The Saudi Food and Drug Authority (SFDA)



Pomalidomide SPC[®] (Pomalidomide)

This patient is on pomalidomide.

Information for patients:

- You MUST tell your prescriber immediately if you experience any symptom that causes concern
- You MUST inform your prescriber immediately if you suspect that you or your female partner is pregnant.

Version: 1.0
Date: December 2022

This document has been reviewed and approved
by The Saudi Food and Drug Authority (SFDA)

Emergency contact information:

Prescription date:

DD / MM / YYYY

Has the patient received counselling?:

Yes / No

Childbearing potential assessment:

WCBP / WNCBP / Male

This patient is receiving pomalidomide for treatment of:

- Multiple Myeloma or
- Relapsed and Refractory Multiple Myeloma

Information for patients and healthcare professionals:

Pomalidomide is an immunomodulator and is an expected human teratogen therefore;

- Female patients of childbearing potential must use at least one effective method of contraception and male patients with pregnant partners or partners of childbearing potential not using effective contraception must use condoms (even if man has had a vasectomy)

- Female patients of childbearing potential must have regular pregnancy tests to ensure that they are not pregnant, except in the case of confirmed tubal sterilisation.